Načítá se...
Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD(2) antibody ch14.18/CHO
Immunotherapy with short term infusion (STI) of monoclonal anti-GD(2) antibody (mAb) ch14.18 (4 × 25 mg/m(2)/d; 8–20 h) in combination with cytokines and 13-cis retinoic acid (RA) prolonged survival in high-risk neuroblastoma (NB) patients. Here, we investigated long-term infusion (LTI) of ch14.18 p...
Uloženo v:
| Vydáno v: | MAbs |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Taylor & Francis
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5800385/ https://ncbi.nlm.nih.gov/pubmed/29120699 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2017.1402997 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|